STAT+: Genentech is soliciting research that can be used to blunt pharma reforms in Washington
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Genentech launched a grant program offering up to $125,000 per award to academics and researchers to produce papers on pharma policy, with a June 30 deadline.
- Genentech’s request for proposals targets three topics: the impact of U.S. drug pricing policies on future innovation, the view of drug discovery as a strategic national asset, and the risks to R&D.
- Genentech intends the funded research to be used to blunt or influence upcoming pharmaceutical reform efforts in Washington.
- Genentech frames the initiative as needed to clarify biopharmaceutical innovation’s role in addressing U.S. healthcare affordability, access, and long‑term system sustainability.
Why it matters: Genentech gains a research pipeline to sway lawmakers, while reform advocates lose a potential counter‑argument; the $125k grants and June 30 deadline aim to influence upcoming drug‑pricing legislation.
